{"doi":"10.1101/2022.03.22.485330","title":"Structure-based Evolution of G protein-biased μ-opioid Receptor Agonists","abstract":"Abstract The μ-opioid receptor (μOR) is the major target for opioid analgesics. Activation of μOR initiates signaling through G protein pathways as well as through β-arrestin recruitment. μOR agonists that are biased towards G protein signaling pathways demonstrate diminished side effects. PZM21, discovered by computational docking, is a G protein biased μOR agonist. Here we report the cryoEM structure of PZM21 bound μOR in complex with G i protein. Structure-based evolution led to multiple PZM21 analogs with more pronounced G i protein bias and increased lipophilicity to improve CNS penetration. Among them, FH210 shows extremely low potency and efficacy for arrestin recruitment. We further determined the cryoEM structure of FH210 bound to μOR in complex with G i protein and confirmed its expected binding pose. The structural and pharmacological studies reveal a potential mechanism to reduce β-arrestin recruitment by the μOR, and hold promise for developing next-generation analgesics with fewer adverse effects. Table of Contents Graphical Abstract We obtained cryoEM structures of the μ-opioid receptor (μOR) bound to the lead compound PZM21 and the newly developed agonist FH210 to understand the mechanism of their biased signaling and to guide the evolution of next-generation analgesics with fewer adverse effects.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2022,"id":306711,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9503,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1001417,"name":"Florian Hetzer","orcid":null,"position":1,"is_corresponding":false},{"id":810521,"name":"Weijiao Huang","orcid":"0000-0002-6253-7765","position":2,"is_corresponding":false},{"id":485170,"name":"Qianhui Qu","orcid":"0000-0002-5753-2599","position":3,"is_corresponding":false},{"id":642233,"name":"Justin Meyerowitz","orcid":"0000-0001-7194-8286","position":4,"is_corresponding":false},{"id":1001085,"name":"Jonas Kaindl","orcid":"0000-0002-8310-5398","position":5,"is_corresponding":false},{"id":349029,"name":"Harald Hübner","orcid":"0000-0002-7892-599X","position":6,"is_corresponding":false},{"id":226976,"name":"Georgios Skiniotis","orcid":"0000-0003-0238-7846","position":7,"is_corresponding":false},{"id":251465,"name":"Brian K. Kobilka","orcid":"0000-0001-5958-3990","position":8,"is_corresponding":false},{"id":349033,"name":"Peter Gmeiner","orcid":"0000-0002-4127-197X","position":9,"is_corresponding":false},{"id":644199,"name":"Haoqing Wang","orcid":"0000-0003-0277-3018","position":0,"is_corresponding":true}],"reference_count":28,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:32:52.703737Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}